2-[2-(3,4-dichlorophenyl)ethyl]-2,5-diazabicyclo[3.0.4]nonane | 1026371-45-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 2-[2-(3,4-dichlorophenyl)ethyl]-2,5-diazabicyclo[3.0.4]nonane
• 英文别名: 1-[2-(3,4-dichlorophenyl)ethyl]-3,5,6,7,8,8a-hexahydro-2H-imidazo[1,2-a]pyridine
• CAS: 1026371-45-8
• 化学式: C₁₅H₂₀Cl₂N₂
• 分子量: 299.243
• InChiKey: XLQFAWRWSVNDFI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Aralkyl diaxabicycloalkane derivatives for CNS disorders
  申请人：——

  公开号：US20020045624A1

  公开（公告）日：2002-04-18

  Certain aralkl diazabicycloalkyl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychoses and convulsions. Compounds of particular interest are of the formula: 1 wherein each of R 1 , R 4 , R 5 , R 6 and R 7 is independently selected from hydrido, lower alkyl, benzyl, and haloloweralkyl; wherein each of R 2 , R 3 and R 8 through R 11 is independently selected from hydrido, hydroxy, loweralkyl, benzyl, phenols, benzyloxy and haloloweralkyl; wherein n is an integer of from four to six; wherein m is an integer of from two to four; wherein A is selected from phenyl, naphthyl, benzothienyl, benzofuranyl and thienyl; wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; or a pharmaceutically acceptable salt thereof.

  本文描述了某些阿拉克尔二氮杂双环烷化合物，用于治疗中枢神经系统疾病，如脑缺血、精神病和抽搐。特别感兴趣的化合物的公式为：1其中R1、R4、R5、R6和R7中的每一个独立选择自氢、低级烷基、苯甲基和卤代低级烷基；其中R2、R3和R8至R11中的每一个独立选择自氢、羟基、低级烷基、苯甲基、酚、苯氧基和卤代低级烷基；其中n为4至6的整数；其中m为2至4的整数；其中A选择自苯基、萘基、苯并噻吩基、苯并呋喃基和噻吩基；其中任何上述A基团都可以进一步用一个或多个取代基独立选择自氢、羟基、低级烷基、低级烷氧基、卤素、卤代低级烷基、氨基、单低级烷基氨基和双低级烷基氨基取代；或其药学上可接受的盐。
• Method of treating proliferative diseases using Eg5 inhibitors
  申请人：——

  公开号：US20020165240A1

  公开（公告）日：2002-11-07

  The invention provides a method for treating a condition via modulation of the Eg5 protein activity comprising administering to a mammalian species in need of such treatment an effective amount of at least one small molecule Eg5 protein inhibitor. The invention also provides a method for treating a condition via modulation of the Eg5 protein activity comprising administering to a mammalian species in need of such treatment an effective amount of at least one small molecule Eg5 protein inhibitor in combination with at least one other anti-cancer agent.

  本发明提供了一种通过调节Eg5蛋白活性治疗疾病的方法，包括向需要此类治疗的哺乳动物物种中给予至少一种小分子Eg5蛋白抑制剂的有效量。本发明还提供了一种通过调节Eg5蛋白活性治疗疾病的方法，包括向需要此类治疗的哺乳动物物种中给予至少一种小分子Eg5蛋白抑制剂和至少一种其他抗癌剂的有效量。
• Sigma-2 receptor agonists and their use in the treatment of HIV infection
  申请人：Bowen D. Wayne

  公开号：US20060004036A1

  公开（公告）日：2006-01-05

  The present invention relates to sigma-2 receptor agonists and their use in the treatment of immunodeficiency virus infections, especially human immunodeficiency virus (HIV) infections. The invention particularly relates to sigma-2 agonists, especially CB-184 and its analogues, that decrease cellular production of sphingomyelin when provided to recipient cells, and inhibit HIV replication.

  本发明涉及sigma-2受体激动剂及其在治疗免疫缺陷病毒感染，特别是人类免疫缺陷病毒（HIV）感染中的用途。本发明尤其涉及σ-2激动剂，特别是CB-184及其类似物，当提供给受体细胞时，它们能减少细胞产生鞘磷脂，并抑制HIV的复制。
• US6310064B1
  申请人：——

  公开号：US6310064B1

  公开（公告）日：2001-10-30
• US6656930B2
  申请人：——

  公开号：US6656930B2

  公开（公告）日：2003-12-02